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Despite advances in intensive care and the widespread use of standardized care included in the Surviving Sepsis
Campaign Guidelines, sepsis remains a leading cause of death, and the prevalence of sepsis increases concurrent
with the aging process. The diagnosis of sepsis was originally based on the evidence of persistent bacteremia
(septicemia) but was modified in 1992 to incorporate systemic inflammatory response syndrome (SIRS). Since then,
SIRS has become the gold standard for the diagnosis of sepsis. In 2016, the Society of Critical Care Medicine and
the European Society of Intensive Care Medicine published a new clinical definition of sepsis that is called Sepsis-3.
In contrast to previous definitions, Sepsis-3 is based on organ dysfunctions and uses a sequential organ failure
(SOFA) score as an index. Thus, patients diagnosed with respect to Sepsis-3 will inevitably represent a different
population than those previously diagnosed. We assume that this drastic change in clinical definition will affect not
only clinical practice but also the viewpoint and focus of basic research. This review intends to summarize the
pathophysiology of sepsis and organ dysfunction and discusses potential directions for future research.
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There have been significant advances in intensive care and
the widespread use of standardized care in the Surviving
Sepsis Campaign Guidelines. However, sepsis remains a
leading cause of death and its prevalence increases con-
current with the aging process. In 2016, the Society of
Critical Care Medicine and the European Society of Inten-
sive Care Medicine published a new clinical definition of
sepsis that is termed as Sepsis-3. This new definition was
subsequently endorsed by a range of affiliated societies, in-
cluding the Japanese Society of Intensive Care Medicine
and the Japanese Association for Acute Medicine (JAAM).
The consensus of opinion indicates that Sepsis-3 will lead
to significant changes in the concept of sepsis [1].
The diagnosis of sepsis was historically based on the evi-
dence of persistent bacteremia (septicemia). However, in
accordance with the progress in our understanding of the
pathophysiology of sepsis, the definition was greatly modi-
fied in 1992 to exclude bacteremia and to incorporate
parameters related to systemic inflammation (Sepsis-1),Correspondence: fujishim@keio.jp
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(SIRS) [2] (Fig. 1). At the same time, two severe subgroups
of sepsis were defined as severe sepsis and septic shock.
Although the definition of sepsis was reevaluated and
modified to include a wider range of parameters in 2003
(Sepsis-2), SIRS continues to be widely used for diagnos-
ing sepsis in various clinical settings [3]. However, the
inadequate specificity and sensitivity of the SIRS criteria
were recognized as a significant limitation and, thus, were
omitted from Sepsis-3 [4]. In contrast to previous defini-
tions, Sepsis-3 is based on organ dysfunctions and sepsis
is diagnosed when there is an increase of more than 2
points in the total sequential organ failure assessment
(SOFA) score; thus, patients diagnosed with respect to
Sepsis-3 will inevitably represent a different population
from those diagnosed with respect to Sepsis-1 or Sepsis-2.
Therefore, we assumed that this drastic change in clinical
definition will not only affect clinical practice, especially
the evaluation of patients with suspected infection, but
also lead to changes in the focus of basic research. In
this review, we intend to provide an overview of the
pathophysiology of sepsis-induced organ dysfunctionle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Schematic diagram showing the previous and new
definitions of sepsis. Asterisk indicates a small fraction of infected
patients develop organ dysfunction without fulfilling the established
SIRS criteria. SIRS systemic inflammatory response syndrome
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cating the direction of the research in this field.Pathophysiology of sepsis
Infection is initiated by the local invasion of microorgan-
isms into a living body. When the host’s immune system
is healthy and the quantity and virulence of the microor-
ganisms involved are below a tolerance limit, infection is
restricted and spontaneously cures. However, if microor-
ganisms overcome a host’s immunological self-defense
system, they can locally extend or spread to distant tissues
and organs via the blood stream. In response to the sys-
temic invasion of microorganisms, the body triggers the
production of inflammatory mediators and characteristic
signs and symptoms, such as fever or hypothermia, tachy-
cardia, tachypnea, and an increase or decrease in periph-
eral white blood cell counts develop, all of which are
essential components of the SIRS criteria. It was at this
stage that the diagnosis of sepsis was made with re-
spect to the former definition, which often predis-
posed the failure of vital organs, currently referred to
as multiple organ dysfunction syndrome (MODS).
Thus, sepsis diagnosed with respect to the Sepsis-3
definition, namely infection-induced single or multiple
organ dysfunctions, is more advanced and manifests
with more severe conditions than that diagnosed by
previous definitions.
Pathogen-derived substances with immunological
properties, notably lipopolysaccharide (LPS), are referred
to as pathogen-associated molecular patterns (PAMPs)
and have been shown to induce sepsis-like conditions
in vivo and activate immune cells in vitro [5]. Injured
tissues also release a set of molecules with similar prop-
erties, including high-mobility group box 1 (HMGB-1)and histones, collectively referred to as damage (dan-
ger)-associated molecular patterns (DAMPs) [6]. Under
septic conditions, PAMPs and DAMPs bind to specific
cell-surface or cytosolic proteins that are called pattern
recognition receptors, which are located on monocytes/
macrophages, vascular endothelial cells, and other stro-
mal cells, and that trigger the activation of intracellular
signaling cascades [7]. Activated cells release various
humoral mediators, particularly cytokines, which accel-
erate local and systemic inflammations.
Cytokines are classified as pro-inflammatory and
anti-inflammatory, and the time course of their expres-
sions vary. Pro-inflammatory cytokines play major roles
in inducing systemic inflammation and in the develop-
ment of MODS. Among the pro-inflammatory cytokines,
tumor necrosis factor alpha (TNFα) and interleukin 1beta
(IL-1β) are detected in the blood of patients with sepsis
and are known to induce septic shock-like conditions
when administered to animals in vivo, thus suggesting
their key pathogenic roles in sepsis [8, 9]. In contrast,
anti-inflammatory cytokines contribute to the regulation
and resolution of acute inflammation, while also contrib-
uting to the immunosuppression and hypersensitivity to
infection that is observed during the later phase of sepsis.
Sepsis-associated lung dysfunction: ARDS
Lung dysfunction, referred to as acute respiratory distress
syndrome (ARDS) or acute lung injury (ALI), is frequently
associated with sepsis. In our recent epidemiological ana-
lysis, ALI was complicated in 40.2 % of patients with se-
vere sepsis or septic shock and had a significantly poor
outcome [10]. A previous report revealed that sepsis-
related ARDS was associated with a poorer outcome than
non-sepsis-related ARDS [11]. An increase in microvascu-
lar permeability, resulting from the dysregulation of cell-
to-cell interaction or tissue destruction, is the fundamental
pathophysiology underlying ARDS. Extensive investigation
has revealed the prominent contribution of neutrophils,
which are major terminal effector cells in innate immun-
ity, to tissue injury in ARDS [12, 13]. Neutrophils have
also been shown to play a role in the dysfunction of other
organs. Neutrophils release granular enzymes, reactive
oxygen metabolites, bioactive lipids, and cytokines [14]
and can induce the formation of neutrophil extracellular
traps [15], most of which can either directly or indirectly
injure tissues, leading to an increase in microvascular per-
meability and resulting in pulmonary edema. Interleukin 8
(also called CXCL8), a potent neutrophil chemotactic che-
mokine, also plays important roles in the pathophysiology
of ARDS, along with TNFα and IL-1β, which represent
major players in septic shock [16]. In addition, some
DAMPs have been recently recognized as mediators or
cytokines with respect to their regulated production
and immune-regulating functions. A pathogenic role of
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binding protein, was initially reported in sepsis [17] and
later in sepsis-associated ARDS [18]. Mitochondrial
DAMPs can stimulate PMNs and induce a sepsis-like
state and ALI [19]. Along with neutrophil-mediated tis-
sue injury, apoptosis and autophagy are also involved in
sepsis-induced tissue injuries that are associated with
ARDS [20, 21]. However, these findings did not lead to
the development of appropriate clinical therapeutics.Dysfunction of other organs in sepsis
As mentioned in the above section, sepsis is often com-
plicated with organ dysfunctions other than ARDS.
Table 1 summarizes the pathophysiology, clinical fea-
tures, SOFA score indices, and available treatments for
individual organ dysfunctions. The type of failure or dys-
function observed in each organ is relatively stereotyped
and most are associated with poor outcomes [22, 23].
Sepsis-derived systemic shock and resultant tissue hypo-
perfusion commonly contribute to the development of
most organ dysfunctions, which is supported by the
findings that early goal-directed therapy (EGDT), a
protocol-based therapeutic intervention involving fluid
resuscitation, improved the MODS score and outcome
[24]. Furthermore, plasma pro-inflammatory cytokine
levels were significantly reduced in an EGDT group
compared with a control group, suggesting that global
tissue ischemia is an important contributor to the earlyTable 1 Organ dysfunction in sepsis
Target organ Pathophysiology Clinical fea
Lung (ARDS) Vascular hyper-permeability, neutrophil
accumulation
Impaired o
Liver Disturbed intracellular and extracellular
bile salt transport
Jaundice, c
Kidney (AKI) Tubular epithelial cell injury, dysfunction






Myocardial depression, impaired intracellular

























SOFA sequential organ failure assessment, ARDS acute respiratory distress syndrome
injury, GFR glomerular filtration ratio, SDD selective digestive decontamination, SAE
intravascular coagulation, FDP fibrin degradation productinflammatory response in sepsis [25]. However, as the
mere recovery of systemic circulation by fluid resuscita-
tion and inotropic agents is insufficient to completely
restore organ function, other injurious mechanisms are
most certainly involved.
During infection, the liver plays critical roles in modu-
lating host defense and regulating inflammation, mostly
via the clearance of pathogens and PAMPs, and in pro-
ducing acute phase proteins such as C-reactive protein
and serum amyloid A [26, 27]. A previous study revealed
through a multivariate analysis that liver cirrhosis was
associated with a 2.4-fold increase in sepsis mortality
[28]. Our analysis and that of other groups showed that
10–17 % of patients with severe sepsis were complicated
with hepatic dysfunction [22, 23], which was shown to
be associated with a poorer clinical outcome in a large
observational study [23]. Sepsis-associated hepatic dys-
function is clinically recognized by jaundice or cholestasis
and is caused by various underlying mechanisms such as
the impairment of energy-dependent bile and bile acid
transport by hypoxia, hypoperfusion, and overproduced
cytokines. No treatments are currently established for
such conditions.
The kidneys are the main controllers of water and
electrolyte metabolism under normal physiological con-
ditions, and the roles of the kidneys become even more
important during sepsis for maintaining vital organ cir-
culation and cellular electrolyte balance and for protect-
ing the lungs from life-threatening pulmonary edema.tures SOFA score indices
(other beneficial indices)
Available treatments
xygenation PaO2/FIO2 <400 (bilateral
infiltration on CXR)
Mechanical ventilation with


















Not included Proton pump inhibitor, early
enteral nutrition, probiotics,
SDD












, CXR chest X-ray, PEEP positive end-expiratory pressure, AKI acute kidney
sepsis-associated encephalopathy, GCS Glasgow coma scale, DIC disseminated
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kidney injury (AKI) and was observed in 37–40 % of
cases with severe sepsis [22, 23]. AKI is clinically detected
as an increase in serum creatinine level or a decrease in
urine volume and is associated with poorer clinical out-
comes [22, 23, 28]. Renal tubular epithelial cell injury,
which is because of disturbed microcirculation and
hypoxia, as well as the dysfunction or adaptive response
of tubular epithelial cells, including the downregulation
of metabolism and cell cycle arrest, is induced by ex-
cessive inflammation and represents a key feature of
AKI [29]. Although hemodialysis has been established
as a clinical therapy for AKI, no strategy to prevent
AKI or to help patients recover from AKI has been
developed.
Blood coagulation and fibrinolysis systems contribute
in the maintenance of systemic and organ circulation
against various injuries to the living body. Under the
condition of sepsis, these systems tend to dysfunction,
a condition referred to as disseminated intravascular
coagulation (DIC), which induces organ dysfunction
and is closely associated with higher mortality. The
major pathophysiology of DIC includes the generalized
activation of intravascular coagulation, microvascular
damage, systemic thrombin generation, and endothelial
injury [30]. There are several diagnostic criteria for
DIC, such as those by JAAM, the International Society
on Thrombosis and Haemostasis (ISTH), and the Japanese
Ministry of Health, Labour and Welfare, with increasingly
reduced levels of sensitivity in this order. The SOFA score
used in the new Sepsis-3 definition includes platelet
counts as a parameter for DIC. In retrospective and pro-
spective studies, DIC was observed in 18–41 % by ISTH
and 47 % by the JAAM criteria [31–33]. Although several
potentially effective drugs have been clinically used, such
as antithrombin III and recombinant thrombomodulin,
their efficacy in terms of survival and protection against
MODS remains to be clarified.
In addition to the abovementioned organs, it is
known that the functions of the cardiovascular system,
gastrointestinal tract, and central nervous system are
often impaired during sepsis and are crucial for patient
outcome. Although some therapies, including beta-
blockers for the cardiovascular system, early enteral nu-
trition for the gastrointestinal tract, and light sedation/
early rehabilitation for the central nervous system, are
potentially effective, their efficacy is limited. Conse-
quently, new organ-specific strategies based on a novel
insight into the pathophysiology should be explored.Future directions for sepsis research
Previous research in both animal models and patients re-
vealed that sepsis is inevitably associated with excessiveinflammation. However, anti-inflammatory strategies
have failed to demonstrate clear benefit in terms of pa-
tient outcome. To begin a new era of clinical practice
for sepsis, it is important to consider the appropriate
direction for future research. The introduction of new
clinical definition may provide us a favorable opportun-
ity to change our emphasis with regard to research.
Although the true causal relationship between individ-
ual organ dysfunction and clinical outcome remains
unresolved, the extent of organ dysfunction and the
total number of dysfunctional organs involved are both
associated with increased mortality, rendering attempts
to protect or recover from organ dysfunction as a
promising approach for sepsis research. Although the
lungs will continue to be the main target, all vital or-
gans could be possible targets for research.
In most preclinical experiments on sepsis, LPS or
pathogens were administered to small animals, and the
post-mortem characteristics of single organs and survival
rates were evaluated. However, the function of multiple
organs would usually be impaired in such models and
additively or synergistically affect the outcome, in a
manner similar to real human patients. Consequently, in
future research, simultaneous evaluation of dysfunction
in more than two vital organs will be mandatory in such
sepsis models. Additionally, the pathophysiology and
therapeutic strategy for individual organ dysfunction
should be more extensively examined using existing or
newly developed single organ dysfunction models, in-
cluding the septic ARDS model via the intratracheal ad-
ministration of pathogens or PAMPs.
For such investigations, it is important to develop
novel techniques to sequentially monitor organ function
hopefully in vivo. To begin with, such research would be
significantly enhanced by developing small-scale appar-
atus to monitor the partial pressure or saturation of
arterial blood oxygen and arterial blood pressure. In
addition, it would be important to incorporate measure-
ments of serum bilirubin, creatinine, and urea nitrogen
for in vivo monitoring across a range of animal models.
In contrast, novel strategies need to be developed to en-
able the evaluation of species-specific parameters such
as blood cells and proteins involved in the coagulation
and fibrinolysis systems.
Conclusions
Excessive inflammation has been established as the key
feature of sepsis pathophysiology and therefore a prime
target of intervention. This understanding led us to the
concept of SIRS, and sepsis was defined as the infection-
induced SIRS. However, anti-inflammatory strategies
have failed to improve clinical outcome in patients with
sepsis. As described earlier, the definition of sepsis was
drastically modified in 2016 so as not to include SIRS
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now clinically defined by an increase in SOFA score.
Thus, patients diagnosed with Sepsis-3 will inevitably
represent a population different from that previously di-
agnosed. We assume that this drastic change in clinical
definition will affect not only clinical practice but also
the direction of future basic research.
Simultaneously evaluating multiple organ dysfunction in
animal models of sepsis or investigating single organ
dysfunction models will enable the development of poten-
tial organ-protective treatments in a robust experimental
manner. Such organ-targeted investigations will certainly
strengthen our understanding of the pathophysiology of
sepsis and may help to develop truly effective therapies to
protect or recover from organ dysfunction in sepsis.
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